annual review

Pfizer Releases 2017 Annual Review

Blog

Pfizer released its 2017 Annual Review, which highlights how The Power of Science drives every aspect of Pfizer’s business in its mission to deliver innovative medicines and vaccines that help improve health and well-being at every stage of life.

This year’s integrated report uses the lens of our colleagues to illustrate how The Power of Science inspires the work they do every day. Highlights include:

Pfizer’s Progress on 2020 Reduced Water Use Goals

Multimedia with summary

Pfizer believes in the importance of reducing human impact on the environment. As part of this, the company has pledged to reduce water use by five percent by 2020.

See Pfizer’s progress toward reduced water consumption in our annual review at www.pfizer.com/annual.

 

Stockland Releases Its 2017 Annual Review and Sustainability Reporting

Article

Stockland has released its FY17 Annual Review and Sustainability Reporting, which highlight its continued leadership and ongoing achievements in sustainability.
 
Mark Steinert, Managing Director and CEO Stockland, said: “These reports demonstrate the shared value we create for our securityholders, customers, community and the environment through the world-leading sustainability initiatives we’re implementing across our business. 
 

Pfizer Expands Health Care Infrastructure in Underserved Communities

Blog

An individual’s ability to access quality health care is often limited where infrastructure is weak or non-existent. By supporting collaborative and entrepreneurial approaches that aim to build and improve health infrastructure, we are giving organizations and individuals the skills and resources they need to drive better global health outcomes.

Pfizer Is Accelerating the Supply Chain

Multimedia with summary

Through a Highly Orchestrated Supply Network (HOSuN) approach, Pfizer has developed a supply chain that is directly sensitive to patient needs and can speed our response to those needs. Enhanced with technological advances, we are able to track movement of product throughout the entire supply chain.

Pfizer Progress on 2020 Environmental Sustainability Goals

Blog

Pfizer has had two successful Greenhouse Gas (GHG) reduction goals which resulted in reductions of GHG emissions by roughly half from 2000 to 2014. We are working hard to meet our third GHG reduction goal to reduce emissions 20 percent further by 2020 from a 2012 baseline. This latest goal has been recognized as a Science Based Target by an initiative led by the Carbon Disclosure Project, the United Nations Global Compact, the World Resources Institute and the World Wildlife Fund.

Compared with a 2012 baseline, by the end of 2020 Pfizer has the goal to reduce:

Pfizer Supports the UN Global Goals for Sustainable Development

Blog

For Pfizer, Sustainable Development Goal 3: Good Health and Well-Being, is inextricably linked to our belief that every individual deserves to lead a long, healthy and productive life. Good health is fundamental to advancing all of the 17 SDGs, each of which is connected to advances in public health.

Bringing Resources to Bear to Improve Global Health

Blog

At Pfizer, we believe our business and societal missions are the same: ensuring all individuals everywhere have access to quality medicines, vaccines and health care, and the opportunity to lead healthy lives. Every day, we strive to use our full resources – our people, products and funding – to find new ways to positively impact the health of people around the world and across their lifespan.

Pfizer’s Progress on 2020 Waste Reduction Goals

Multimedia with summary

In alignment with the global sustainable development goals, Pfizer has committed to reduce its total hazardous and non-hazardous waste disposal by 15 percent by 2020. 

Learn more about Pfizer’s progress in waste reduction: www.pfizer.com/annual

Using the Power of Technology & Innovative Science to Advance Patient Care

Multimedia with summary

There have been great strides made recently in treating the most difficult and debilitating health conditions people face. Yet, there is still much work to be done if we are going to find truly effective therapies for these conditions. At Pfizer, we work to make our drug development process more efficient by collaborating with unique partners and exploring new pathways that harness technology and emerging science.

Pages

Subscribe to annual review